W.G. Shaheen & Associates Dba Whitney & CO Affimed N.V. Transaction History

W.G. Shaheen & Associates Dba Whitney & CO

$856 Million
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Feb 07, 2019	SELL	$2.82 - $4.67 $282 - $467	-100 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$1.45 - $6.15 $145 - $615	100 New	100 $0

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

Tekla Capital Management LLC

586K
Shares

$1.91 Million
0.01% of portfolio
Act Capital Management, LLC Wayne, PA

309K
Shares

$1.01 Million
0.88% of portfolio
Telemetry Investments, L.L.C. New York, NY

200K
Shares

$652,000
0.39% of portfolio

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $487M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of W.G. Shaheen & Associates Dba Whitney & CO, based on Form 13F filings with the SEC.

News

Stay updated on W.G. Shaheen & Associates Dba Whitney & CO with notifications on news.

Account